Korea:145020

Hugel launches botulinum toxin Letybo in Malaysia

- The company strengthens brand experience for local medical professionals through academic events and hands-on workshops - It will solidify the market position of premium toxin products through Malaysian partner Venusys Medical SEOUL, South Korea, Aug. 10, 2025 /PRNewswire/ -- Hugel Inc., a lea...

2025-08-11 08:30 1613

Hugel achieves record net sales, profit, net income in 2024

- The company reports KRW373.0 billion in net sales, KRW166.3 billion in operating profit, andKRW142.4 billion in net income, reflecting year-over-year increases of 16.7%, 41.2%, and 45.8%, respectively - More international revenue contributions to expect in 2025 with key new toxin market l...

2025-02-13 14:11 1974

ITC final initial determination Ruled in favor of Hugel (no violation of Section 337)

SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- Hugel Inc, a global total medical aesthetics company, announced that the Administrative Law Judge (ALJ) for its U.S. International Trade Commission(ITC) investigation issued an initial determination onJune 10th (local time) finding that "there is ...

2024-06-11 11:33 2428

Hugel Appointed Suk-yong Cha as Executive Chairman and Chairman of the Board Accelerating Transformation into a Global Top-tier Company

- Appointed as Executive Chairman and Chairman of the Board at the General Meeting of Shareholders and Board of Directors meeting on the 30th - Chairman Cha will lead the growth of Hugel based on his aesthetics know-how and experience in pioneering global markets SEOUL, South Korea, March 31, 20...

2023-03-31 20:00 2566

Hugel Nominates Suk-yong Cha as Non-Executive Director

* Hugel's 22nd General shareholders' meeting to take place on March 30th * Proposed appointment of Suk-yong Cha as new non-executive director as an agenda item SEOUL, South Korea, March 9, 2023 /PRNewswire/ -- Hugel, a global total medical aesthetic company, announced onMarch 9th that it wil...

2023-03-09 23:00 2739

Hugel Achieved Record-High Revenue and Operating Profit

* Hugel delivered 2022 revenue of KRW281.7bn, operating profit of KRW102.5bn, up 21.5% YoY and 7.2% YoY, respectively * Botulinum toxin's sales soared by 28.9% YoY; European sales in full swing * Hugel aims to obtain marketing approval and launch products in the U.S. within this year SEOUL, ...

2023-02-09 22:00 3118

Hugel's 'Letybo' First in Korea to Obtain Marketing Approval from Australia

- Obtained marketing approval on the 23rd (local time) from the Therapeutic Goods Administration (TGA) ofAustralia for the indication of glabellar lines - First shipment and local launch planned for Q1 2023...Plans to cooperate with major chain clinics and key opinion leaders SEOUL, South Korea,...

2022-11-24 22:00 5804

Hugel resubmits BLA for its botulinum toxin, Botulax to the U.S. FDA

* Hugel received CRL from the U.S. FDA last March and completely supplemented documents and data. * It is expected to obtain the U.S. FDA's approval in the first half of 2023 and aims to become a TOP 3 botulinum toxin brand in the U.S. market. SEOUL, South Korea, Oct. 7, 2022 /PRNewswire/ -- ...

2022-10-08 11:00 2489